Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03383679
Title Study on Androgen Receptor and Triple Negative Breast Cancer (START)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors UNICANCER
Indications

triple-receptor negative breast cancer

Therapies

Darolutamide

Capecitabine

Age Groups: adult | senior
Covered Countries


No variant requirements are available.